Gemcitabine plus sorafenib versus gemcitabine alone in advanced biliary tract cancer: A double-blind placebo-controlled multicentre phase II AIO study with biomarker and serum programme
European Journal of Cancer2014Vol. 50(18), pp. 3125–3135
Citations Over TimeTop 10% of 2014 papers
Markus Moehler, Annett Maderer, C Schimanski, Stephan Kanzler, U Denzer, Frank T. Kolligs, M. Ebert, Andrea Distelrath, Michael Geißler, Jörg Trojan, M.M. Schutz, L. Berie, C. Sauvigny, Frank Lammert, AW Lohse, Matthias Dollinger, Udo Lindig, Eva–Maria Duerr, Nikolaus Lubomierski, S.J. Zimmermann, Daniel Wachtlin, A. Kaiser, Simin Schadmand‐Fischer, Peter R. Galle, Marcus A. Woerns
Abstract
The addition of sorafenib to gemcitabine did not demonstrate improved efficacy in advanced BTC patients. Biomarker subgroup analysis suggested that some patients might benefit from combined treatment.
Related Papers
- → Su2004 Gemcitabine Plus Cisplatin Versus Gemcitabine Chemotherapy for Advanced Biliary Tract Cancer(2013)1 cited
- Long-lasting tumour response to sorafenib therapy in advanced hepatocellular carcinoma.(2014)
- → Faculty Opinions recommendation of Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.(2010)1 cited
- → 6595 POSTER Phase I Study of Gemcitabine as a Fixed Dose Rate Infusion and S-1 Combination Therapy (FGS) in Gemcitabine-refractory Biliary Tract Cancer (BTC) Patients(2011)
- → Faculty Opinions recommendation of Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.(2010)